Back to top
more

Sanofi (SNY)

(Real Time Quote from BATS)

$57.68 USD

57.68
1,943,026

+0.05 (0.09%)

Updated Sep 23, 2024 09:46 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (79 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Kinjel Shah headshot

Sanofi Stock Up Almost 23% in 3 Months: Buy, Sell or Hold?

by Kinjel Shah

SNY's reasonable valuation, rising estimates, improving top line and positive pipeline progress are good enough reasons to stay invested in the stock.

AZN Gets FDA Nod for Fasenra Label Expansion in Rare Disease

by Zacks Equity Research

The FDA okays AstraZeneca's Fasenra for treating adults with eosinophilic granulomatosis with polyangiitis. This is the second approved indication for the drug.

Andrew Rocco headshot

Why Novavax is Gaining Ground in COVID-19 Vaccine Race

by Andrew Rocco

Though Novavax is behind in the COVID-19 vaccine race, a blockbuster deal with Sanofi and a differentiated product means the stock offers the best reward prospects in the industry.

Regeneron, SNY Win FDA Approval for a Broader Dupixent Label

by Zacks Equity Research

REGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.

MRNA Stock Falls 12% on Lowered Sales Outlook, R&D Budget Cuts

by Zacks Equity Research

As part of its strategic prioritization, Moderna aims to cut its R&D expenses by 20% over the next four years. It decides to end five pipeline programs to save costs.

Kinjel Shah headshot

TEVA Stock Rises 72.5% This Year: Time to Buy, Sell or Hold?

by Kinjel Shah

Teva's reasonable valuation, an improving pipeline and the prospect of growth in sales and profits are good enough reasons for those who own the stock to stay invested.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Approves J&J's Tremfya for Ulcerative Colitis & More

by Kinjel Shah

FDA approves J&J's Tremfya for ulcerative colitis. NVO's oral obesity pill, amycretin, shows faster weight loss than weekly injection, Wegovy.

Sanofi, Regeneron's Dupixent Meets Late-Stage Urticaria Study Goals

by Zacks Equity Research

This is the second pivotal late-stage study on SNY/REGN's Dupixent in chronic spontaneous urticaria indication to meet primary and key secondary endpoints.

GSK's Respiratory Drug Nucala Meets Goal in COPD Study

by Zacks Equity Research

GSK announces positive data from a phase III study of Nucala (mepolizumab) in chronic obstructive pulmonary disease (COPD).

Eli Lilly's Weekly Insulin Shot Meets Two Late-Stage Study Goals

by Zacks Equity Research

Data from two late-stage studies show that LLY's once-weekly insulin injections achieved results that are similar to daily insulin shots.

Kinjel Shah headshot

Pharma Stock Roundup: EU Nod for Expanded Use of MRK's Keytruda & More

by Kinjel Shah

European Commission approves expanded use of Merck's Keytruda in bladder cancer. Sanofi & Lilly announce data from phase III studies on pipeline candidates.

Novavax Stock Up 9% on FDA Nod for Updated COVID-19 Vaccine

by Zacks Equity Research

The FDA authorization for NVAX's updated COVID-19 vaccine makes it the only non-mRNA vaccine option in the country.

SNY's MS Drug Meets Goal in One Phase III Study; Misses in Two Others

by Zacks Equity Research

Sanofi's HERCULES phase III study on tolebrutinib meets primary endpoint, showing an improvement in delaying time to onset of confirmed disability progression.

Regeneron's Bispecific Antibody Obtains EC Nod for Lymphoma

by Zacks Equity Research

REGN's oncology portfolio gets a boost with the approval of odronextamab for treating follicular lymphoma and diffuse large B-cell lymphoma (DLBCL).

Regeneron (REGN) Gets CRL From FDA for Multiple Myeloma Drug

by Zacks Equity Research

Regeneron (REGN) suffers a delay in obtaining FDA approval of linvoseltamab for the treatment of relapsed/refractory multiple myeloma.

Kymera (KYMR) to Raise $225 Million Through Offering of Shares

by Zacks Equity Research

Kymera (KYMR) is in the process of selling approximately 2 million shares of common stock at a public offering price of $40.75 per share, along with pre-funded warrants to purchase 3,519,159 shares in the offering.

Kinjel Shah headshot

How Should You Play AstraZeneca (AZN) After Q2 Beat, View Raise?

by Kinjel Shah

AstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga should drive sales. Its pipeline is huge, with several candidates having blockbuster potential.

The Zacks Analyst Blog Highlights Meta Platforms, Sanofi, CME and The Cato

by Zacks Equity Research

Meta Platforms, Sanofi, CME and The Cato are part of the Zacks top Analyst Blog.

Sheraz Mian headshot

Top Stock Reports for Meta, Sanofi & CME

by Sheraz Mian

Today's Research Daily features new research reports on 12 major stocks, including Meta Platforms, Inc. (META), Sanofi (SNY) and CME Group Inc. (CME), as well a micro-cap stock The Cato Corporation (CATO).

Novavax (NVAX) Lags on Q2 Earnings & Sales, Cuts '24 Outlook

by Zacks Equity Research

Novavax (NVAX) posts dismal second-quarter results. It also slashes its total revenue guidance, citing lower COVID-19 vaccine uptake.

Kymera (KYMR) Q2 Loss Narrower Than Expected, Pipeline in Focus

by Zacks Equity Research

Kymera (KYMR) reports a narrower-than-expected loss in the second quarter. The company expects the current cash balance to provide a runway into the first half of 2027.

The Zacks Analyst Blog AstraZeneca, Ionis and Sanofi

by Zacks Equity Research

AstraZeneca, Ionis and Sanofi are included in this Analyst Blog.

Regeneron (REGN) Q2 Earnings Gain From Eylea HD, Dupixent

by Zacks Equity Research

Regeneron's (REGN) decent second-quarter results can be attributed to strong uptake of Eylea HD sales and high Dupixent profits, even though lead drug Eylea is under pressure.

Sundeep Ganoria headshot

Novavax (NVAX) Stock Before Q2 Earnings: To Buy or Not to Buy?

by Sundeep Ganoria

On Novavax's (NVAX) second-quarter earnings call, investors will likely focus on the company's pipeline updates and collaboration revenue numbers from its recently entered deal with Sanofi.

Regeneron (REGN) Tops on Q2 Earnings, Eylea HD, Dupixent Fuel Sales

by Zacks Equity Research

Regeneron (REGN) reports strong Q2 results, wherein both the top and bottom lines beat estimates due to higher Eylea HD and Libtayo sales and profits from Dupixent sales.